No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ARCT250117C2500
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover1139.15%IV-86.10%PremiumJan 17, 2025Expiry Date15.48Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9805Delta0.0018Gamma1.13Leverage Ratio-0.0997Theta0.0003Rho1.11Eff Leverage0.0011Vega
Intraday
- 5D
- Daily
No Data
News
Arcturus Therapeutics Launches Phase I Avian Influenza Trials in US
Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial
Express News | Arcturus Therapeutics Holdings Inc - Interim Phase 1 Data Expected H2 2025
Express News | Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
Piper Sandler Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $140
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns